[Distribution of CD8+CD28- T cells and CD3+CD56+ NKT cells in peripheral blood of patients with B-cell non-Hodgkin's lymphoma].
OBJECTIVE
Patients with B-cell non-Hodgkin's lymphoma (B-NHL) usually have a poor immune response. CD8(+)CD28(-) T cells (Ts) and CD3(+)CD56(+) NKT cells (NKT) are new types of immune suppressor cells. This study was to analyze proportions and changes of them in peripheral blood of patients with B-NHL, explore their effects on immunosuppression of B-NHL, and the influnce factors, to provide reference for intervening in immune function of B-NHL patients.


METHODS
Peripheral blood samples were got from 79 naive patients with B-NHL before treatment, and 25 healthy people, samples of 18 patients who got complete remission (CR) after 4-6 cycles of chemotherapy were collected either before chemotherapy or after CR. Proportions of Ts and NKT were analyzed by flow cytometry (FCM).


RESULTS
Compared with control group, proportions of Ts, and NKT in peripheral blood of B-NHL patients before chemotherapy were (18.19+/-5.03)%, and (6.08+/-3.29)%, significantly higher than those of healthy people [(11.20+/-3.49)%, P< 0.01; (3.52+/-1.56)%, P< 0.01]. There were no significant differences of proportions of Ts among patients with B-NHL of different clinical stages (P >0.05), and different malignant grade (P >0.05), and between before treatment and after CR (P=0.55). No significant difference of proportions of NKT was found among patients with B-NHL of different clinical stages (P >0.05), and different malignant grade (P >0.05), and between before treatment and after CR (P=0.39).


CONCLUSIONS
Populations of Ts and NKT commonly increased in peripheral blood of patients with B-NHL, they may play roles in immunosuppression of B-NHL.
Shi
Yan-Xia
YX
Department of Medical Oncology, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, 510060, P.R.China.
Zhang
Xiao-Shi
XS
Liu
Dong-Geng
DG
Guan
Zhong-Zhen
ZZ
Jiang
Wen-Qi
WQ
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D018106:CD28 Antigens / Q000097:blood; D017252:CD3 Complex / Q000097:blood*; D019002:CD56 Antigen / Q000097:blood; D016827:CD8 Antigens / Q000097:blood; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D005260:Female; D006801:Humans; D007694:Killer Cells, Natural / Q000276:immunology*; D018655:Lymphocyte Count; D016393:Lymphoma, B-Cell / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D012074:Remission Induction
D018106:CD28 Antigens; D017252:CD3 Complex; D019002:CD56 Antigen; D016827:CD8 Antigens